NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
September 12, 2024 16:04 ET
|
NurExone Biologic Inc
NurExone Biologic Enhances Visibility in Pharmaceutical Industry with Technological Presentations at Major Global Events
Crescendo Biologics to present at the 2024 AACR Annual Meeting
March 06, 2024 07:00 ET
|
Crescendo Biologics
Crescendo Biologics to present at the 2024 AACR Annual Meeting Cambridge, UK, 6 March 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno-oncology company developing novel, targeted...
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
January 24, 2024 07:00 ET
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
January 24, 2024 03:00 ET
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign
November 01, 2023 07:00 ET
|
Jonathan Milner
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign CAMBRIDGE, England, 1 November 2023 - Jonathan Milner, the founder and one of the largest investors in Abcam plc...
Arecor: Business Update
July 20, 2023 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated...
Coherus to Acquire Surface Oncology
June 16, 2023 07:01 ET
|
Surface Oncology, Inc.
– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – ...
OBSS CodeMaster coding contest continues with Cambridge after Oxford
March 28, 2023 05:00 ET
|
OBSS TEKNOLOJI ANONIM SIRKETI
Business simulation coding contest takes place in world-class universities in the UK: Oxford, Cambridge and Imperial College, offering €30,000 grand prize Top 3 Oxford students received their prizes...
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
March 09, 2023 07:00 ET
|
Surface Oncology, Inc.
SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8...
OBSS CodeMaster expands into the UK, coding contest takes place in Oxford & Cambridge with €30,000 grand prize
March 03, 2023 07:00 ET
|
OBSS TEKNOLOJI ANONIM SIRKETI
Software development and technology company OBSS Technology, conducts CodeMaster coding contest with a legacy of more than 10 years. On its 11th year, OBSS CodeMaster online coding contest expands...